muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.

Published on Jul 31, 2020in Trials1.883
· DOI :10.1186/S13063-020-04618-2
Ing Ni Lu1
Estimated H-index: 1
(Cambridge University Hospitals NHS Foundation Trust),
Spoorthy Kulkarni3
Estimated H-index: 3
(Cambridge University Hospitals NHS Foundation Trust)
+ 11 AuthorsJoseph Cheriyan20
Estimated H-index: 20
(Cambridge University Hospitals NHS Foundation Trust)
OBJECTIVES: To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance 3 OR ≥3 if risk count includes "Radiographic severity score >3". A risk count is calculated by the following features on admission (1 point for each): radiographic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x109/L, age >40 years and CRP >40 mg/L. Patients should be considered an appropriate subject for intervention with immunomodulatory or other disease modifying agents in the opinion of the investigator and are able to swallow capsules or tablets. The complete inclusion and exclusion criteria as detailed in the Additional file 1 should be fulfilled. Drug specific inclusion and exclusion criteria will also be applied to the active arms. Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support. Participants will be recruited across multiple centres in the UK including initially at Cambridge University Hospitals NHS Foundation Trust and St George's University NHS Foundation Trust. Other centres will be approached internationally in view of the evolving pandemic. INTERVENTION AND COMPARATOR: There is increasing evidence of the role of immunomodulation in altering the course of COVID-19. Additionally, various groups have demonstrated the presence of pulmonary shunting in patients with COVID-19 as well as other cardiovascular complications. TACTIC-E will assess the efficacy of the novel immunomodulatory agent EDP1815 versus the approved cardio-pulmonary drugs, Dapagliflozin in combination with Ambrisentan versus the prevailing standard of care. EDP1815 will be given as 2 capsules twice daily (1.6 x 1011 cells) for up to 7 days with the option to extend up to 14 days at the discretion of the principal investigator or their delegate, if the patient is felt to be clinically responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment course. Ambrisentan 5mg and Dapagliflozin 10mg will be given in combination once daily orally for up to maximum of 14 days. Patients will be randomised in a 1:1:1 ratio across treatments. Each active arm will be compared with standard of care alone. Additional arms may be added as the trial progresses. No comparisons will be made between active arms in this platform trial. MAIN OUTCOMES: The primary outcome is the incidence (from baseline up to Day 14) to the occurrence of the any one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). RANDOMISATION: Eligible patients will be randomised using a central web-based randomisation service (Sealed Envelope) in a 1:1:1 ratio, stratified by site to one of the treatment arms or standard of care. BLINDING (MASKING): This is an open-label trial. Data analysis will not be blinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): There is no fixed sample size for this study. There will be an early biomarker-based futility analysis performed at a point during the study. If this biomarker futility analysis is not conclusive, then a second futility analysis based on clinical endpoints will be performed after approximately 125 patients have been recruited per arm. Provisionally, further analyses of clinical endpoints will be performed after 229 patients per active arm and later 469 patients per arm have been recruited. Further additional analyses may be triggered by the independent data monitoring committee. TRIAL STATUS: TACTIC-E Protocol version number 1.0 date May 27th, 2020. Recruitment starts on the 3rd of July 2020. The end trial date will be 18 months after the last patient's last visit and cannot be accurately predicted at this time. TRIAL REGISTRATION: Registered on EU Clinical Trials Register EudraCT Number: 2020-002229-27 registered: 9 June 2020. The trial was also registered on (NCT04393246) on 19 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
📖 Papers frequently viewed together
12 Citations
5 Citations
21 Authors (Ellen Gorman, ..., Daniel F. McAuley)
11 Citations
Cited By6
#1Danielle Brain (University of Liverpool)
#2Alex Plant-Hately (University of Liverpool)
Last. Neill J. Liptrott (University of Liverpool)H-Index: 16
view all 8 authors...
The emergence of SARS-CoV-2, and the ensuing global pandemic, has resulted in an unprecedented response to identify therapies that can limit uncontrolled inflammation observed in patients with moderate to severe COVID-19. The immune pathology behind COVID-19 is complex and involves the activation and interaction of multiple systems including, but not limited to, complement, inflammasomes, endothelial as well as innate and adaptive immune cells to bring about a convoluted profile of inflammation,...
#1Fotios Barkas (RMIT: RMIT University)H-Index: 11
#2Georgia Anastasiou (RMIT: RMIT University)H-Index: 3
Last. Evangelos Liberopoulos (RMIT: RMIT University)H-Index: 50
view all 4 authors...
The present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76-0.95, p = 0.004; I 2 = 0, p = 0.48). Supplementary information null The online version contains supplementary material available at 10.1007/s13340-021-00515-4.
#1Marie Fisk (University of Cambridge)H-Index: 10
#2Magnus Althage (AstraZeneca)H-Index: 5
Last. Joseph Cheriyan (University of Cambridge)H-Index: 20
view all 11 authors...
The novel coronavirus 2019 (COVID-19) infection caused by SARS-CoV-2 is a global pandemic that requires a multi-faceted approach to tackle this unprecedent health crisis. Therapeutics to treat COVID-19 are an integral part of any such management strategy and there is a substantial unmet need for treatments for individuals most at risk of severe disease. This perspective review provides rationale of a combined therapeutic regimen of selective endothelin-A (ET-A) receptor antagonism and sodium glu...
#1Anastasiou G (UoA: National and Kapodistrian University of Athens)H-Index: 1
#1Georgia Anastasiou (UoA: National and Kapodistrian University of Athens)H-Index: 3
Last. Evangelos Liberopoulos (RMIT: RMIT University)H-Index: 50
view all 3 authors...
ABSTRACT: Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (Coronavirus Disease-2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patients With COVID-19), an ongoing clinical trial, is designed to investigate the impact of dapagliflozin on COVID-19 progression. This article discusses the potential favorable impact ...
1 CitationsSource
#1Rosalinda Madonna (UniPi: University of Pisa)H-Index: 38
Abstract Although results from two major trials trials have shown a clear benefit of gliflozines in the management of heart failure (HF) irrespective of diabetes status, the mechanism of cardiac benefits remains incompletely understood. Gliflozines have an osmotic diuretic effect that differs from that of other diuretic classes, resulting in greater electrolyte-free water clearance, and clinical studies have shown that intravascular volume depletion is rare and occurs at similar frequency in the...
Last. Rafael de Carvalho Mendes (Estácio S.A.)H-Index: 3
view all 4 authors...
Devido a pandemia da COVID-19, varios pesquisadores estao buscando estrategias farmacologicas para o tratamento dessa enfermidade. Neste artigo pretende-se expor os alvos farmacologicos mais relevantes encontrados na literatura e que estao frequentemente sendo utilizados no tratamento da COVID-19. Foi realizada uma revisao de literatura por meio de busca nas bases de dados eletronicas: SciELO e PubMed, para tanto, utilizou-se os seguintes descritores: Farmacos “Drugs”, Tratamento “Treatment” e C...